According to a publication of 2019 entitled "Blau syndrome associated with nucleotide-binding oligomerization domain containing 2 mutations in a baby from Malaysia", this has been seen that due to rarity of the disease and lack of awareness, along with a limited number of genetic tests led to late diagnosis or even misdiagnosis of the disease.
Access full Report @ https://www.databridgemarketresearch.com/reports/global-blau-syndrome-market
Global Blau syndrome market is expected to reach USD 12,856.08 thousand by 2027 from USD 5,566.40 thousand in 2019 growing with a CAGR of 11.9% in the forecast period of 2020 to 2027. The demand for Blau syndrome treatment has increased in both developed and developing countries, and the reason behind this is the high demand for disease-specific treatment worldwide. The Blau syndrome market is growing due to the high adoption of biological therapies, emergence of drugs used to treat symptoms associated with Blau syndrome, advancement in the healthcare industry and the availability of off-label drugs, among others.
Emergence of drugs used for the treatment of uveitis and nephritis, symptoms related to Blau syndrome across the world will drive the market's growth rate
Blau syndrome can affect various body parts. Most people with this syndrome also develop uveitis, which leads to inflammation in the middle layer of the eye, uvea. Moreover, patients having this syndrome also develop kidney disease that is nephritis, and nephrocalcinosis. As various symptoms are associated with Blau syndrome, different drugs, and treatment options have emerged for the treatment of Blau syndrome. This signifies that the emergence of drugs used for treating uveitis and nephritis, symptoms related to Blau syndrome, is expected to drive the market growth.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2020 to 2027
|
Base Year
|
2019
|
Historic Years
|
2018 (Customizable to 2013 - 2018)
|
Quantitative Units
|
Revenue in USD Thousand, Volumes in Units, Pricing in USD
|
Segments Covered
|
Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
Countries Covered
|
U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
|
Market Players Covered
|
Eli Lilly and Company (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Johnson & Johnson Private Limited (U.S.), Teva Pharmaceutical Industries Ltd.(Jerusalem), Merck & Co., Inc. (U.S.), Allergan (Ireland), Bausch Health Companies Inc. (Canada), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Sanofi (France), Merck KGaA (Germany), Otsuka America Pharmaceutical, Inc. (U.S.), Akorn Operating Company LLC (U.S.), Allostera Pharma Inc. (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT Pharmaceuticals (New Zealand), Novaliq GmbH (Germany) among others
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
Global Blau syndrome market is categorized into five notable segments on the basis of type, therapeutic areas, route of administration, end-user and distribution channel.
The hospitals segment will dominate the end user segment of the Blau syndrome market
The hospitals segment will emerge as the dominating segment end user segment. This is because of the growing number of hospitals in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.
The hospital pharmacy segment will dominate the distribution channel segment of the Blau syndrome market
The hospital pharmacy segment will emerge as the dominating segment under distribution channel with approximately 50.00% market share. This is because of the growing number of infrastructural development activities in the market, especially in developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in Blau syndrome market: Eli Lilly and Company (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Johnson & Johnson Private Limited (U.S.), Teva Pharmaceutical Industries Ltd.(Jerusalem), Merck & Co., Inc. (U.S.), Allergan (Ireland), Bausch Health Companies Inc. (Canada), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Sanofi (France), Merck KGaA (Germany), Otsuka America Pharmaceutical, Inc. (U.S.).
Market Development
Regional Analysis
Geographically, the countries covered in the Blau syndrome market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
As per Data Bridge Market Research analysis:
North America is the dominant region in Blau syndrome market during the forecast period 2020 - 2027
North America is expected to dominate the market due to the region's high healthcare and research & development expenditure.
Asia-Pacific is estimated to be the fastest-growing region in Blau syndrome market the forecast period 2020 - 2027
Asia-Pacific is expected to grow with the highest CAGR in the forecasted periods due to increasing healthcare expenditure by the hospital in medical devices in the region and increasing prevalence of autoimmune inflammatory diseases.
COVID-19 Impact
The COVID-19 epidemic has had a disastrous effect on the population and economy of the entire world. Healthcare systems are under a lot of stress as a result of the pandemic. In order to reduce the risk of transmission and save money for COVID-19 patients, healthcare institutions and providers have been directed to halt performing elective surgical operations and medical evaluations during this time. However, pharmaceutical and biotechnological industries are expected to grow at a staggering rate, which will positively impact the world.
For more detailed information about the Blau syndrome on market report, click here – https://www.databridgemarketresearch.com/reports/global-blau-syndrome-market
Global Blau syndrome Market – Industry Trends and Forecast to 2030
North America Blau Syndrome Market – Industry Trends and Forecast to 2030
Europe Blau Syndrome Market – Industry Trends and Forecast to 2030
Middle East and Africa Blau Syndrome Market – Industry Trends and Forecast to 2030
Asia-Pacific Blau Syndrome Market – Industry Trends and Forecast to 2030